One Nucleus is pleased to announce the shortlist for the One Nucleus Awards 2026.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision, and enabling support across the stakeholders.Best Preclinical Stage R&D of the Year:⭐ Axiom Therapeutics⭐ LinkGevity⭐ Immutrin⭐C-Further⭐Asgard TherapeuticsBest Clinical Stage R&D of the Year:⭐ CellCentric⭐ Alchemab Therapeutics Ltd⭐ Hemab Therapeutics⭐ Muna Therapeutics⭐ Resolution TherapeuticsBest Use of Emerging Technology of the Year:⭐ deepmirror⭐ Luvida⭐ ExpressionEdits⭐ Unravel Health…
Pivotal, which specializes in developing and managing clinical trials for the pharmaceutical and biotechnological industry, receives this recognition for the strength of its management model, the quality of its processes, and its commitment to scientific innovation.
Madrid, September 24, 2026 — The Comunidad de Madrid regional government has awarded the Madrid Excelente quality seal to Pivotal, Spain's first CRO (Clinical Research Organisation), in recognition of a management model built on quality, scientific rigor, and innovation. The distinction cements Pivotal's position as one of the…
Delivering reduced hands-on time, more consistent results and higher sample throughout
Oxford, UK, 24th September.
OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamiton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.
Rising sample volumes are putting clinical research labs under pressure. Maintaining consistent…
Amsbio announce a new partnership with Atelerix to introduce its patented hydrogel technology for the room-temperature storage and transportation of living cells, tissues, organoids and viruses.
Preserving cell functionality during storage and transportation is challenging for cell-based therapies as cryopreservation methods can compromise cell viability and functionality. The novel hypothermic hydrogel technology, available from Amsbio, offers a revolutionary alternative, addressing many of the issues associated with cryopreservation.
This seaweed-derived hydrogel forms a protective…
New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.
DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.
Regulatory Spark is designed to help founder-led biotech companies, scientific founders, academic spinouts, and tech transfer teams understand their likely route to…
Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.
Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions.
Barry Callebaut has moved to the site to bolster its long-term presence at Colworth Science Park, home to The Magnum Ice Cream Company (TMICC). The move reinforces Barry Callebaut’s commitment to the local innovation…
Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face.
Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart.
Despite their vital work for those with rare diseases, the value of patient…
Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific
Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer
Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s co-founder and former CEO, transitions to the role…
Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.
Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.
By leveraging its specialist clinical and regulatory expertise in novel medicinal products including cell and gene therapy development, Boyds has successfully navigated uncertainty across its clients’ markets, which…
LONDON, UK; MADRID, Spain; and SHORT HILLS, NJ – September 16, 2026 – Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.The appointments expand Coulter Partners' capabilities across Europe and North America, including the…